CXCL13 has emerged as a promising biomarker in RA, with its level in the synovium associated with the presence of synovial lymphoid aggregates, autoantibody positivity, and erosive disease [110, 111]. The gene discussed is CXCL13; the disease is rheumatoid arthritis.